INDOSAT
28.2.2023 11:55:38 CET | Business Wire | Press release
President Director and CEO of Indosat Ooredoo Hutchison (Indosat), Vikram Sinha, discussed the story of Indosat, the most successfully merger that empowers Indonesia. Indosat is the new world-class digital telecoms and internet company for Indonesia resulting from the merger of Indosat Ooredoo and Hutchison 3 Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005739/en/
Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison (Photo: Business Wire)
During the roundtable discussion, Sinha highlighted that telco mergers often fail for various reasons, such as difficulty integrating different technologies and systems, regulatory hurdles, and challenges in retaining key personnel and customers. However, Indosat's successful merger has transformed the telecommunications industry and Indonesia's GDP growth.
Indonesia is one of the fastest-growing economies in the world and one of the most prominent digital economies in ASEAN. Digital adoption enables Indonesia to reduce the time to realize its long-term goal of achieving high-income status. Indosat, a digital telco with 100 million subscribers, is transforming rapidly to help drive the digital revolution in the country.
Sinha discussed how the merger of Indosat Ooredoo and Hutchison 3 Indonesia had exceeded all expectations for 2022, giving a positive outlook for Indonesia's market and the opportunity to grow in the telco industry. Indosat has an ongoing 9-quarter integration plan, and the realization of their synergies is running smoothly and has been completed ahead of the plan. Using Multi-Operator Core Networks (MOCN) technology, their network integration is targeted to be completed this quarter.
Indosat launched a research report titled Empowering Indonesia 2023, which reviews the pillars of Indonesia's digital economy and the role of technology in accelerating its future growth. The report shows that Indosat is the primary driver of the telecommunications industry and Indonesia's GDP growth, fueled by its solid growth in 2022.
Indosat's Full-Year 2022 Result shows a solid performance both financially and operationally. Total revenue increased by 48.9% YoY, EBITDA was recorded at Rp19,468.7 billion, and net profit for the year attributable to parent company owners was Rp4,723.4 billion, normalized net profit increased by 76.2% YoY. The company's cellular customers increased by 62.5% to 102.2 million for FY 2022.
"We have defied expectations and become the successful merger in the world. Indosat is not just good for the industry; it's good for Indonesia. We will continue to drive the digital revolution and create value for all our stakeholders," said Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison.
About Indosat Ooredoo Hutchison
Indosat Ooredoo Hutchison (IDX: ISAT)’s vision is to become the most preferred digital telco of Indonesia. Through its world-class digital telecom services and preeminent network, Indosat Ooredoo Hutchison strives to connect and empower every Indonesian. Jointly controlled by Ooredoo Group and CK Hutchison, Indosat Ooredoo Hutchison was formed through the merger of PT Indosat Tbk and PT Hutchison 3 Indonesia in 2022.
Website: www.IOH.co.id
YouTube: https://www.youtube.com/channel/UChs2x7pZ2D8UgHz9cgrn3sQ
Facebook: https://www.facebook.com/indosat
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005739/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom